Biochanin A inhibits lung adenocarcinoma progression by targeting ZEB1

Lung adenocarcinoma is the major subtype of lung cancer, accounting for approximately 40% of lung cancers. During clinical treatment, the emergence of chemotherapy resistance seriously affects the effectiveness of treatment. Thus, finding new chemotherapeutic sensitizers is considered to be one of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianjun, Kou, Yaqi, Zhang, Xiaohan, Xiao, Xuechun, Ou, Yang, Cao, Lixia, Guo, Min, Qi, Chunchun, Wang, Zhaoyang, Liu, Yuxin, Shuai, Qiuying, Wang, Hang, Yang, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748019/
https://www.ncbi.nlm.nih.gov/pubmed/36512117
http://dx.doi.org/10.1007/s12672-022-00601-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748019/
https://www.ncbi.nlm.nih.gov/pubmed/36512117
http://dx.doi.org/10.1007/s12672-022-00601-2

Ejemplares similares